SaNOtize lands $24m in Series B round to grow research program

Horizons Ventures and OurCrowd led the round with participation from ABC International.

  • The funding enables SaNOtize to expand its research program
  • The company was founded in 2017
  • SaNOtize’s Nitric Oxide Nasal Spray (NONS) has been clinically shown to treat COVID-19 in high-risk adult patients and to prevent infections when used after known exposure to SARS-CoV-2.

SaNOtize Research and Development Corp, a Vancouver-based anti-infective-focused therapeutics company, has raised $24 million in Series B financing. Horizons Ventures and OurCrowd led the round with participation from ABC International.

The funding enables SaNOtize to expand its research program, including its ongoing global Phase 3 Nitric Oxide Nasal Spray (NONS) prevention clinical study with plans to recruit up to 3,000 participants in Canada and Sri Lanka.

NONS is currently authorized for use in countries throughout Europe, the Middle East and Asia. It has been clinically shown to treat COVID-19 in high-risk adult patients and to prevent infections when used immediately after known exposure to SARS-CoV-2.

“We are thrilled to embark on these new partnerships, as they empower SaNOtize to accelerate its research program in various therapeutic fields and expand our Phase 3 NONS COVID-19 trial to additional countries,” said Gilly Regev, PhD, SaNOtize Co-Founder and CEO. “Our clinical and observational studies found NONS to be safe and effective at both treating and preventing COVID-19, even amid delta and omicron surges. We look forward to expanding our clinical research and working toward regulatory approval in the United States and Canada.”

“We are excited about SaNOtize’s Nitric Oxide Releasing Solution platform technology (NORS™️), bringing about highly affordable and effective treatment and prevention to a range of bothersome upper respiratory and topical infections, bettering health and wellness with an impactful option,” said Frances Kang, portfolio curator of Horizons Ventures, who was recently appointed to the SaNOtize board of directors.

SaNOtize was founded in 2017.